Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies.
Imipenem plasma concentrations were analyzed in 57 febrile neutropenic patients using the NONMEM program. The recommended 2-g/day regimen achieved coverage of the most common bacteria (MIC(90) = 1 mg/liter) during the whole dosing interval in only 53% of patients. This goal was achieved in 90% of patients with 3 g/day.
Lamoth
F
F
Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland.
Buclin
T
T
Csajka
C
C
Pascual
A
A
Calandra
T
T
Marchetti
O
O
D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005919:Glomerular Filtration Rate; D017408:Guidelines as Topic; D019337:Hematologic Neoplasms / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D015378:Imipenem / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D009503:Neutropenia / Q000139:chemically induced* / Q000150:complications*; D055815:Young Adult
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D015378:Imipenem